The canine prostate cancer cell line CHP-1 shows over-expression of the co-chaperone small glutamine-rich tetratricopeptide repeat-containing protein α

D. Azakami, R. Nakahira, Y. Kato, M. Michishita, M. Kobayashi, E. Onozawa, M. Bonkobara, M. Kobayashi, K. Takahashi, Masami Watanabe, K. Ishioka, T. Sako, K. Ochiai, T. Omi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Although androgen therapy resistance and poor clinical outcomes are seen in most canine prostate cancer cases, there are only a few tools for analysing canine prostate cancer by using a cell biological approach. Therefore, to evaluate androgen-independent neoplastic cell growth, a new canine prostate cancer cell line (CHP-1) was established in this study. CHP-1 over-expressed the co-chaperone small glutamine-rich tetratricopeptide repeat-containing protein α (SGTA), which is over-expressed in human androgen-independent prostate cancer. The CHP-1 xenograft also showed SGTA over-expression. Although CHP-1 shows poor androgen receptor (AR) signalling upon dihydrotestosterone stimulation, forced expression of AR enabled evaluation of AR signalling. Taken together, these results suggest that CHP-1 will be a useful model for investigating the pathogenesis of androgen-dependent and androgen-independent canine prostate cancer.

Original languageEnglish
JournalVeterinary and Comparative Oncology
DOIs
Publication statusAccepted/In press - 2016

    Fingerprint

Keywords

  • Androgen receptor signalling
  • Canine
  • Prostate cancer
  • Small glutamine-rich tetratricopeptide repeat-containing protein α

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Azakami, D., Nakahira, R., Kato, Y., Michishita, M., Kobayashi, M., Onozawa, E., Bonkobara, M., Kobayashi, M., Takahashi, K., Watanabe, M., Ishioka, K., Sako, T., Ochiai, K., & Omi, T. (Accepted/In press). The canine prostate cancer cell line CHP-1 shows over-expression of the co-chaperone small glutamine-rich tetratricopeptide repeat-containing protein α. Veterinary and Comparative Oncology. https://doi.org/10.1111/vco.12199